Gadopiclenol, sold under the brand name Elucirem or Vueway among others, is a contrast agent used with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system and in the body. Gadopiclenol is a paramagnetic macrocyclic non-ionic complex of gadolinium.
Gadopiclenol, sold under the brand name Elucirem or Vueway among others, is a contrast agent used with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system and in the body. Gadopiclenol is a paramagnetic macrocyclic non-ionic complex of gadolinium.
Gadopiclenol was approved for medical use in the United States in September 2022, and in the European Union in December 2023. Developed initially by Guerbet with intellectual property contributions from Bracco Imaging, gadopiclenol was commercialized following a strategic collaboration between the companies for manufacturing, research, and distribution.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).